Clinical Trial Update: Effect of 7 Days of Dosing With a 10 mg Rectal Suppository of NRL001in Patients With Faecal Incontinence [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating 7 days of 10 mg rectal NRL001 in patients with fecal incontinence has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fecal Incontinence

Drugs mentioned

• NRL001

Snippet

Sponsor: Norgine | Conditions: Fecal Incontinence | Phase 1 | Status: COMPLETED